**Charity Registration No. 285946**
**Company Registration No. 493724 (England and Wales)**
**THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2024**
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **LEGAL AND ADMINISTRATIVE INFORMATION**
**Trustees** Dr Zaloa Agirre-Arrizubieta Professor Mark Baker Dr Natalie Ross Dr Sushma Goyal Dr Brython Hywel Dr Stephan Jaiser Dr Samantha Jefferson Professor Martin Koltzenburg Dr Andrew Michell Dr Friederike Moeller Dr Gareth Payne Dr Ronit Pressler Dr Syed Shah Dr Rachel Thornton Dr Simon Freilich (Appointed 6 October 2023) Dr Jiten Mistry (Appointed 6 October 2023) **Charity number** 285946 **Company number** 493724 **Independent examiner** Katherine Dee FCA ACA Begbies Chartered Accountants 9 Bonhill Street London EC2A 4DJ
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **CONTENTS**
||**Page**|
|---|---|
|Trustees' report|1 - 3|
|Independent examiner's report|4|
|Statement of financial activities|5 - 6|
|Summary income and expenditure account|7|
|Balance sheet|8|
|Notes to the financial statements|9 - 19|
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)** _**FOR THE YEAR ENDED 30 JUNE 2024**_
The trustees of The British Society for Clinical Neurophysiology (BSCN) present their report and accounts for the year ended 30 June 2024 and confirm that they comply with current statutory requirements and with the requirements of the Society's governing instrument.
The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charitable company's [governing document], the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).
## **Objectives and activities**
The charitable company's objects are to promote and assist the science and practice of electroencephalography, clinical neurophysiology and allied subjects.
The policies adopted in furtherance of these objects are as following and there has been no change in these during the year:
1. To organise scientific meetings of the Society (usually 2-3 per year)
2. To organise teaching courses (triennial)
3. To organise essay prizes in the subject
4. To provide an Annual Medical Student Bursary, of up to £5,000, in support of a Neurosciences BSc.
The trustees consider they have have complied with the duty of section 17(5) of the Charities Act 2011, having paid due regard to public benefit guidance issued by the Charity Commission in deciding what activities the charitable company should undertake.
## **Achievements and performance**
Having embraced the technological challenges of running our scientific meetings virtually, out of necessity during the COVID-19 pandemic, the Society has continued to provide a virtual offering. This continues to be popular with the membership, increasing the accessibility to continuing professional development while reducing the need for travel. Both our Autumn meeting in 2023, hosted by the Fetal Medicine Research Institute, London, and Spring Meeting held at the University of Edinburgh were run as hybrid events. All meetings were well attended and the feedback has been good.
In June 2023, we learned at the European Congress of Clinical Neurophysiology (ECCN) meeting in Marseille that the Society had been successful in its bid to host the 2025 ECCN meeting in London. An independent company has been established to organise and administer the ECCN 2025 meeting and thus the Society will be protected from any financial liability. Planning for the event is ongoing.
The BSCN would normally have expected to organise the triennial Oxford teaching course for Spring 2025. However, because the ECCN 2025 meeting will include comparable teaching opportunities to those planned for the Oxford course, a decision was made by Council to postpone the Oxford teaching course for 2025.
The BSCN continues to honour achievement in clinical neurophysiology, and award prizes and grants. The total cost of awards for the 2023/4 year was £7,620.
The Medical Student Essay Prize of £500 which was awarded to Zekai Qiang from Sheffield University.
The Adrian Prize of £1000 was awarded to Rohan Kandasamy from the National Hospital for Neurology and Neurosurgery.
The undergraduate bursary of £5,000 was awarded to Alana Hodgson from Sheffield University.
Book bursaries totalling £1,199 were awarded to eight recipients.
General bursaries totalling £7,000 were awarded to fourteen UK trainees in clinical neurophysiology, providing financial assistance to enable the recipients to attend training courses in neonatal EEG and paediatric EMG.
- 1 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT)** _**FOR THE YEAR ENDED 30 JUNE 2024**_
## Subscriptions
Income from membership subscriptions decreased by 6.6% during the year to 30th June 2024.
## Meetings
Expenses relating to Society meetings amounted to £22.273, and income amounted to £37,203.
These costs are directly attributable to the meetings, and are before the share of governance or support costs.
## Professional fees
Independent Examination for the year were £3,133.
## Investments
The market value of the Society's investments decreased during the year by £5,200 (6.2%). These investments produced dividends and gross interest of £4,488.
## **Financial review**
The Society's financial position remains very sound. This year the Society reports a net surplus for the year of £13,882; however, the Society always aims to break even year on year and leave sufficient funds in order to fund the running of large events, including future triennial teaching courses in Oxford. After the success of the Society’s bid to host the ECCN in 2025, we have been working on the ECCN 2025 budget with a professional conference organiser (PCO), who have set up a limited company, with Dr Nick Kane and Dr Jacquie Deeb as Directors. This will ensure that the Society does not have any financial liability for ECCN 2025 and will not be expected to underwrite the congress. However, given the ECCN will take place instead of the triennial course in 2025, the Society will provide support for the ECCN, as it has previously for the triennial course.
## Reserves policy
The Society holds reserves sufficient to underwrite any potential losses in respect of the next triennial teaching course. At the year end the reserves stood at £214,000, of which £10,000 is held as an expendable endowment for the Dr last Memorial fund and £21,021 are restricted funds. The remaining £182,979 unrestricted funds are freely available to support the charitable objects.
## Investments policy
The Society's investments are held in charity-specific low risk unit trusts and fixed interest securities.
## Risk Mitigation
The trustees have reviewed the Society's exposure to major risks and have accordingly established that the Society's reserves are sufficient to mitigate them.
## **Structure, governance and management**
The charitable company is a company limited by guarantee, and is incorporated in England. The company's registered address is 9 Bonhill Street, London, EC2A 4DJ.
The governing instrument is the Memorandum and Articles of Association (updated October 2021). The society is governed by a council of management, which consists of the Officers of the Society, the Chairmen of the Medical and Clinical Scientists Standing Committees, not more than eight ordinary members of the Council (being corporate members of the Society), and such corporate members of the Society (not exceeding three) as may be co-opted by Council at its discretion.
Trustees (Officers of the Society) are appointed in accordance with the Memorandum and Articles of Association. Persons are nominated for election as officers of the Society at least 6 weeks prior to the Annual General Meeting. If more than one person is nominated, a vote is taken at the AGM, otherwise the election is agreed by the council.
Newly appointed Officers are either already experienced in the role, or share duties and shadow the outgoing Officer.
- 2 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT)** _**FOR THE YEAR ENDED 30 JUNE 2024**_
A new role has been introduced which commenced in 2022 - President Elect - who will shadow the President for two years before serving a two-year term themselves as President.
The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:
Dr Zaloa Agirre-Arrizubieta Professor Mark Baker Dr Natalie Ross Dr Jacquie Deeb (Resigned 6 October 2023) Dr Sushma Goyal Dr Brython Hywel Dr Stephan Jaiser Dr Samantha Jefferson Professor Martin Koltzenburg Dr Andrew Michell Dr Friederike Moeller Dr Gareth Payne Dr Ronit Pressler Dr Syed Shah Dr Elisaveta Sokolov (Resigned 6 October 2023) Dr Rachel Thornton Dr Simon Freilich (Appointed 6 October 2023) Dr Jiten Mistry (Appointed 6 October 2023)
None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £2 in the event of a winding up.
The trustees' report was approved by the Board of Trustees.
..............................
**Dr Gareth Payne** Trustee 3[rd] October 2024 Dated: .........................
- 3 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **INDEPENDENT EXAMINER'S REPORT**
## **TO THE TRUSTEES OF THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
I report to the trustees on my examination of the financial statements of The British Society for Clinical Neurophysiology (the charitable company) for the year ended 30 June 2024.
## **Responsibilities and basis of report**
As the trustees of the charitable company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).
Having satisfied myself that the financial statements of the charitable company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charitable company’s financial statements carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.
## **Independent examiner's statement**
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:
- 1 accounting records were not kept in respect of the charitable company as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.
## **Katherine Dee FCA**
Begbies Chartered Accountants 9 Bonhill Street London EC2A 4DJ
Dated: 30/10/24
- 4 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **STATEMENT OF FINANCIAL ACTIVITIES**
## _**FOR THE YEAR ENDED 30 JUNE 2024**_
|**Current financial year**
**Unrestricted**
**Restricted Endowment**
**funds**
**funds**
**funds**
**2024**
**2024**
**2024**
**Notes**
**£**
**£**
**£**
Income from:
Donations and legacies
**2**
22,162
-
-
Charitable activities
**3**
37,203
-
-
Investments
**4**
5,167
1,244
-
**Total income**
64,532
1,244
-
Expenditure on:
Charitable activities
**5**
67,199
487
-
Net gains/(losses) on investments
**11**
3,596
-
1,604
**Net incoming resources before**
**transfers**
929
757
1,604
Gross transfers between funds
1,604
-
(1,604)
**Net movement in funds**
2,533
757
-
Fund balances at 1 July 2023
182,979
21,020
10,000
**Fund balances at 30 June 2024**
185,512
21,777
10,000|**Total**
**2024**
**£**
22,162
37,203
6,411
65,776
67,686
5,200
3,290
-
3,290
213,999
217,289|Total
2023
**£**
26,935
34,300
4,153
65,388
46,866
(4,640)
13,882
-
13,882
200,118
214,000|
|---|---|---|
The statement of financial activities includes all gains and losses recognised in the year.
The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.
- 5 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **STATEMENT OF FINANCIAL ACTIVITIES (CONTINUED)** _**FOR THE YEAR ENDED 30 JUNE 2024**_
|**Prior financial year**
**Unrestricted**
**Restricted Endowment**
**funds**
**funds**
**funds**
**2023**
**2023**
**2023**
**Notes**
**£**
**£**
**£**
Income from:
Donations and legacies
**2**
23,735
3,200
-
Charitable activities
**3**
34,300
-
-
Investments
**4**
2,945
1,208
-
**Total income**
60,980
4,408
-
Expenditure on:
Charitable activities
**5**
44,153
2,713
-
Net gains/(losses) on investments
**11**
(3,490)
-
(1,150)
**Net incoming resources before transfers**
13,337
1,695
(1,150)
Gross transfers between funds
(1,150)
-
1,150
**Net movement in funds**
12,187
1,695
-
Fund balances at 1 July 2022
170,792
19,326
10,000
**Fund balances at 30 June 2023**
182,979
21,021
10,000|**Total**
**2023**
**£**
26,935
34,300
4,153
65,388
46,866
(4,640)
13,882
-
13,882
200,118
214,000|
|---|---|
The statement of financial activities includes all gains and losses recognised in the year.
The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.
- 6 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **SUMMARY INCOME AND EXPENDITURE ACCOUNT**
## _**FOR THE YEAR ENDED 30 JUNE 2024**_
|**All income funds**
**2024**
**£**
Gross income
65,776
Gains/(losses) on investments
3,596
Transfer from/(to) endowment funds
1,604
Total income in the reporting period
70,976
Total expenditure from income funds
67,686
**Net income for the year**
3,290|**2023**
**£**
65,388
(3,490)
(1,150)
60,748
46,866
13,882|
|---|---|
- 7 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **BALANCE SHEET**
## _**AS AT 30 JUNE 2024**_
|**Notes**
**Fixed assets**
Investments
**13**
**Current assets**
Debtors
**14**
Cash at bank and in hand
**Creditors: amounts falling due within**
**one year**
**16**
**Net current assets**
**Net assets**
**The funds of the charitable company**
Endowment funds
**17**
Restricted income funds
**18**
Unrestricted funds|**2024**
**£**
916
138,903
139,819
(11,419)|**£**
88,889
128,400
217,289
10,000
21,777
185,512
217,289|**2023**
**£**
894
132,696
133,590
(3,279)|**£**
83,689
130,311|
|---|---|---|---|---|
|||||214,000|
|||||10,000
21,021
182,979|
|||||214,000|
For the year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
3[rd] October 2024
The financial statements were approved by the trustees on .........................
Professor Mark Baker
Company registration number 493724 (England and Wales)
- 8 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS** _**FOR THE YEAR ENDED 30 JUNE 2024**_
## **1 Accounting policies**
## **Charity information**
The British Society for Clinical Neurophysiology is a private company limited by guarantee incorporated in England and Wales. The registered office is 9 Bonhill Street, London, EC2A 4DJ.
All of the trustees are members of the company and guarantee to contribute £2 in the event of a winding up.
## **1.1 Accounting convention**
The financial statements have been prepared in accordance with the charitable company's governing document, the Companies Act 2006, FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charitable company is a Public Benefit Entity as defined by FRS 102.
The charitable company has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.
The financial statements are prepared in sterling, which is the functional currency of the charitable company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
## **1.2 Going concern**
At the time of approving the financial statements, the trustees have a reasonable expectation that the charitable company has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.
## **1.3 Charitable funds**
## MSC Fund
The Medical Standing Committee fund was established from the residual reserves of the Association of British Clinical Neurophysiologists, which were donated during the year ended 30 June 2006. No travel expenses were reimbursed from this fund during the year.
## The Christine and Adrian Fowle Prize Fund
This prize fund, established by past president of the society Adrian Fowle and his wife Christine is intended to recognise excellence in the practice of clinical neurophysiology other than in science, and in particular in its human aspects. £5,000 (plus £1,250 of gift aid) was donated to the Society in 2020.
## Dr Last Memorial Fund
This expendable endowment fund was established by a generous donation from Dr Last's family and a contribution from the Society's reserves. Its purpose is to further the objectives of the Society, in particular in assisting younger members, by making grants to support foreign travel, enabling the recipient to visit laboratories where they may wish to learn new techniques or to plan or carry out joint research. It was not originally intended that funds should be used to facilitate attendance at conferences but it has been subsequently agreed that the fund may be used to finance bursaries. The fund originally comprised £10,000 of M & G Charifund units which yield an annual income and provides capital growth. During the year the investment generated investment income of £1,244. The committee will intend to distribute the annual income from the fund and may sell units to give additional finance provided that the market value of the capital invested in the fund does not fall below £10,000. It may make awards to one or more applicants or make no award if applicants are not considered suitable or if insufficient funds are available.
- 9 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 JUNE 2024**_
## **1 Accounting policies**
## **(Continued)**
## **1.4 Incoming resources**
Incoming resources from charitable activities are recognised on an accruals basis. Investment income is received gross and accounted for on an accruals basis.
Cash donations are recognised on receipt. Membership fees are recorded as donations.
No provision has been made in these accounts for subscriptions unpaid at the end of the year. Subscriptions are recognised in full in the year in which they are received.
## **1.5 Resources expended**
Resources expended are recognised in the year in which they are incurred. Support costs are those costs incurred in support of expenditure on the objects of the charity. Governance costs are those incurred in connection with compliance with constitutional and statutory requirements.
## **1.6 Fixed asset investments**
Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.
## **1.7 Cash and cash equivalents**
Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
## **1.8 Financial instruments**
The charitable company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the charitable company's balance sheet when the charitable company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
## _**Basic financial assets**_
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
- 10 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 JUNE 2024**_
## **1 Accounting policies**
## **(Continued)**
## _**Basic financial liabilities**_
Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
## _**Derecognition of financial liabilities**_
Financial liabilities are derecognised when the charitable company’s contractual obligations expire or are discharged or cancelled.
## **2 Donations and legacies**
|**Unrestricted**
**Restricted**
**funds**
**funds**
**2024**
**2024**
**£**
**£**
ECCN grant
-
-
Membership fees
22,162
-
22,162
-
**For the year ended 30 June 2023**
23,735
3,200|**Total**
**2024**
**£**
-
22,162
22,162|Total
2023
£
3,200
23,735|
|---|---|---|
|||26,935|
|||26,935|
## **Donated goods and**
## **services**
The Society were provided cost-free use of a meeting room for the 2022 Autumn Scientific Meeting. The fair value of this facility was measured at £3,000. No such equivalent was received in 2023.
- 11 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 JUNE 2024**_
## **3 Charitable activities**
|Delegate fee income
Exhibitor fee income
Analysis by fund
Unrestricted funds
**For the year ended 30 June 2023**
Unrestricted funds|**2024**
**£**
17,003
20,200
37,203
37,203|**2023**
**£**
19,550
14,750|
|---|---|---|
|||34,300|
|||34,300|
|||34,300|
Income from charitable activities consists of income from three scientific meetings (2023: three), and two courses.
## **4 Investments**
|**Unrestricted**
**Restricted**
**funds**
**funds**
**£**
**£**
Income From Listed Investments
2,923
1,244
Bank Interest
2,244
-
5,167
1,244
**For the year ended 30 June 2023**
2,945
1,208|**Total**
**2024**
**£**
4,167
2,244
6,411|**Total**
**2023**
**£**
4,011
142|
|---|---|---|
|||4,153|
|||4,153|
- 12 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**
## _**FOR THE YEAR ENDED 30 JUNE 2024**_
## **5 Charitable activities**
|**Scientific**
**Meetings**
**Grants and**
**Awards**
**£**
**£**
Meeting costs
22,273
-
Other meeting costs
-
-
22,273
-
Grant funding of activities (see note 6)
-
15,819
Share of support costs (see note 7)
24,198
-
Share of governance costs (see note 7)
5,396
-
51,867
15,819
Analysis by fund
Unrestricted funds
51,380
15,819
Restricted funds
487
-
51,867
15,819
**For the year ended 30 June 2023**
Meeting costs
18,729
-
Other meeting costs
2,713
-
21,442
-
Grant funding of activities (see note 6)
-
1,794
Share of support costs (see note 7)
20,497
-
Share of governance costs (see note 7)
3,133
-
45,072
1,794
Analysis by fund
Unrestricted funds
42,359
1,794
Restricted funds
2,713
-
45,072
1,794|**Total**
**2024**
**£**
22,273
-
22,273
15,819
24,198
5,396
67,686
67,199
487
67,686|**Total**
**2023**
**£**
18,729
2,713|
|---|---|---|
|||21,442
1,794
20,497
3,133|
|||46,866|
|||18,729
2,713|
|||21,442
1,794
20,497
3,133|
|||46,866|
|||44,153
2,713|
|||46,866|
- 13 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**
## _**FOR THE YEAR ENDED 30 JUNE 2024**_
## **6 Grants payable**
|Grants to individuals
**For the year ended 30 June 2023**|**2024**
**£**
15,819
15,819
13,860|**2023**
**£**
1,794|
|---|---|---|
|||1,794|
||||
## Grants and Awards
## 2024
General grants paid by the charitable company, consisting of the Adrian Prize for £1,000, the Christine and Adrian Fowle Prize Fund for £500, the Medical Student Essay Prize for £500, and 11 bursaries of £500 each (totalling £5,500) to reimburse trainees attending the EEG Course in Cambridge.
## 2023
General grants paid by the charitable company, consisting of the Grey Walter Medal, the Medical Student Essay Prize for £500 and a book bursary of £244.
- 14 -
**THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**
## _**FOR THE YEAR ENDED 30 JUNE 2024**_
## **7 Support costs**
|**Support**
**costs**
**Governance**
**costs**
**£**
**£**
Website
6,660
-
Clerical Assistance
15,451
-
Subscription - IFCN
1,149
-
Subscription - JNC
250
-
Bank charges
262
-
Sundry expenses
426
-
Examination fees
-
2,893
Legal and professional
-
2,265
Governance costs heading 1
-
238
24,198
5,396
Analysed between
Charitable activities
24,198
5,396|**2024**
**£**
6,660
15,451
1,149
250
262
426
2,893
2,265
238
29,594
29,594|2023
£
965
16,673
1,227
250
285
1,097
3,133
-
-|
|---|---|---|
|||23,630|
|||23,630|
## 2023
All support costs are attributable to scientific meetings.
## 2022
Clerical Assistance consists of administration support, of which £1,482.35 can be directly attributable to the Teaching Course at Pembroke. Of the remaining administration support costs, based on time spent, 50% relates to meeting administration and 50% relates to non-meeting administration.
Computer costs totalling £296.71 can be directly attributable to the Teaching Course at Pembroke. The remaining support and governance costs have been allocated entirely to scientific meetings.
Governance costs includes accountants' fees of £3,113 (2023- £2,893) for examination fees.
|**8**|**Net movement in funds**|**2024**|**2023**|
|---|---|---|---|
|||**£**|**£**|
||The net movement in funds is stated after charging/(crediting):|||
||Fees payable for the independent examination of the charity's financial|||
||statements|2,893|3,133|
## **9 Trustees**
None of the trustees (or any persons connected with them) received any remuneration or benefits from the charitable company during the year (2022: £0). 3 trustees claimed travel expenses totalling £913 (2022: nil)
- 15 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 JUNE 2024**_
## **10 Employees**
The average monthly number of employees during the year was:
||**2024**|**2023**|
|---|---|---|
||**Number**|**Number**|
|Total|-|-|
There were no employees whose annual remuneration was more than £60,000.
## **Remuneration of key management personnel**
The remuneration of key management personnel was as follows:
## **11 Gains and losses on investments**
||**Unrestricted **|**Endowment**|**Total**|**Unrestricted **|**Endowment**|**Total**|
|---|---|---|---|---|---|---|
||**funds**|**funds**||**funds**|**funds**||
||**2024**|**2024**|**2024**|**2023**|**2023**|**2023**|
|Gains/(losses) arising on:|**£**|**£**|**£**|**£**|**£**|**£**|
|Revaluation of|||||||
|investments|3,596|1,604|5,200|(3,490)|(1,150)|(4,640)|
## **12 Taxation**
The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.
## **13 Fixed asset investments**
|**Listed**
**investments**
**Unlisted**
**investments**
**£**
**£**
**Cost or valuation**
At 1 July 2023
73,689
10,000
Valuation changes
5,200
-
At 30 June 2024
78,889
10,000
**Carrying amount**
At 30 June 2024
78,889
10,000
At 30 June 2023
73,689
10,000
**Debtors**
**2024**
**Amounts falling due within one year:**
**£**
Prepayments and accrued income
916|**Total**
**£**
83,689
5,200|
|---|---|
||88,889|
||88,889|
||83,689|
||**2023**
**£**
894|
## **14 Debtors**
- 16 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**
## _**FOR THE YEAR ENDED 30 JUNE 2024**_
|**15**
**Loans and overdrafts**
Bank overdrafts
Payable within one year|**2024**
**£**
8,140
8,140|**2023**
**£**
-|
|---|---|---|
|||-|
## **16 Creditors: amounts falling due within one year**
|**Notes**
Bank overdrafts
**15**
Accruals|**2024**
**£**
8,140
3,279
11,419|**2023**
**£**
-
3,279|
|---|---|---|
|||3,279|
## **17 Endowment funds**
Endowment funds represent assets which must be held permanently by the charitable company. Income arising on the endowment funds can be used in accordance with the objects of the charitable company and is included as unrestricted income. Any capital gains or losses arising on the assets form part of the fund.
||**At 1 July 2023**|**Transfers**|**Gains and**|**At 30 June**|
|---|---|---|---|---|
||||**losses**|**2024**|
||**£**|**£**|**£**|**£**|
|**Permanent endowments**|||||
||10,000|(1,604)|1,604|10,000|
|**Previous year:**|**At 1 July 2022**|**Transfers**|**Gains and**|**At 30 June**|
||||**losses**|**2023**|
||**£**|**£**|**£**|**£**|
|**Permanent endowments**|||||
||10,000|1,150|(1,150)|10,000|
- 17 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 JUNE 2024**_
## **18 Restricted funds**
The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.
|**At 1 July 2023**
**Incoming**
**resources**
**Resources**
**expended**
**At**
**£**
**£**
**£**
MSC Fund
12,006
-
-
Dr Last Memorial Fund
3,277
1,244
-
Christine and Adrian Fowle Prize Fund
5,250
-
-
Visit Britain ECCN grant
487
-
(487)
21,020
1,244
(487)
**Previous year:**
**At 1 July 2022**
**Incoming**
**resources**
**Resources**
**expended**
**At**
**£**
**£**
**£**
MSC Fund
12,006
-
-
Dr Last Memorial Fund
2,070
1,208
-
Christine and Adrian Fowle Prize Fund
5,250
-
-
Visit Britain ECCN grant
-
3,200
(2,713)
19,326
4,408
(2,713)|**30 June**
**2024**
**£**
12,006
4,521
5,250
-
21,777
**30 June**
**2023**
**£**
12,006
3,278
5,250
487
21,021|
|---|---|
## **19 Unrestricted funds**
The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.
|**At 1 July 2023**
**Incoming**
**resources**
**Resources**
**expended**
**Transfers**
**Gains and**
**losses**
**At**
**£**
**£**
**£**
**£**
**£**
General funds
182,979
64,532
(67,199)
1,604
3,596
**Previous year: At 1 July 2022**
**Incoming**
**resources**
**Resources**
**expended**
**Transfers**
**Gains and**
**losses**
**At**
**£**
**£**
**£**
**£**
**£**
General funds
170,792
60,980
(44,153)
(1,150)
(3,490)|**30 June**
**2024**
**£**
185,512
**30 June**
**2023**
**£**
182,979|
|---|---|
- 18 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 JUNE 2024**_
|**20**
**Analysis of net assets between funds**
**Unrestricted**
**Fund**
**Restricted**
**Funds**
**Endowment**
**Fund**
**£**
**£**
**£**
Fund balances at 30 June 2024 are
represented by:
Investments
88,889
-
-
Current assets/(liabilities)
128,400
-
-
217,289
-
-
**£**
**£**
**£**
Fund balances at 30 June 2023 were
represented by:
Investments
83,689
-
-
Current assets/(liabilities)
109,778
20,533
-
193,467
20,533
-|**Total**
**£**
88,889
128,400|
|---|---|
||217,289|
||**£**
83,689
130,311|
||214,000|
## **21 Related party transactions**
There were no disclosable related party transactions during the year (2023 - none), other than the £500 Adrian & Christine Fowle Prize for 2022 being awarded to Dr J Bland.
- 19 -